強気
$6.00
シナリオ価格
$3.720
-0.359 (-9.65%)終値時点
NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company operates through two segments: NexGel and CGN. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CGN segment comprises is comprised of the CGN JV used for the Company’s converting and packaging business, which is based in Granbury, Texas. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George. It also holds a portfolio of regenerative biomaterials which include Biovance, Biovance 3L, Natalin, and others.
Nexgel Inc is not a good buy right now due to significant financial instability and negative trends. The current price is $3.72, and the company has a troubling year-to-date change of -89.72%, indicating severe underperformance. Additionally, the RSI is at 37.396, suggesting the stock is nearing oversold territory, but this does not guarantee a rebound. The main risk is the upcoming earnings report on November 10, 2026, where the EPS estimate is -4.80, which could further pressure the stock if results disappoint.
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

NEXGEL Regains Nasdaq Compliance with Minimum Bid Price

NEXGEL Stock to Begin Trading on a Split-Adjusted Basis

NEXGEL Reports Q1 Earnings Miss

NEXGEL Appoints New VP of Sales to Drive BIONX Surgical Division Growth

NEXGEL to Report Q1 2026 Financial Results on May 15
NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company operates through two segments: NexGel and CGN. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CGN segment comprises is comprised of the CGN JV used for the Company’s converting and packaging business, which is based in Granbury, Texas. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George. It also holds a portfolio of regenerative biomaterials which include Biovance, Biovance 3L, Natalin, and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Nexgel Inc is not a good buy right now due to significant financial instability and negative trends. The current price is $3.72, and the company has a troubling year-to-date change of -89.72%, indicating severe underperformance. Additionally, the RSI is at 37.396, suggesting the stock is nearing oversold territory, but this does not guarantee a rebound. The main risk is the upcoming earnings report on November 10, 2026, where the EPS estimate is -4.80, which could further pressure the stock if results disappoint.
投稿はまだありません
登録またはログインして議論に参加本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。